FEDERAL COURT OF AUSTRALIA
Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd [2018] FCA 1082
File number: NSD 656 of 2017 Judge: NICHOLAS J Date of judgment: 24 July 2018 Catchwords: PATENTS – legal professional privilege/patent attorney privilege – whether implied waiver – application by patentee to amend patent pursuant to s 105 of Patents Act 1990 (Cth) – delay – where patentee alleges that it did not decide that it would be desirable to amend patent until shortly prior to filing of application under s 105 – whether implied waiver arising from patentee’s pleaded grounds in support of proposed amendments in relation to advice given to patentee concerning amendments made to patent applications filed in other jurisdictions
PRIVILEGE – legal professional privilege/patent attorney privilege – whether implied waiver
Legislation: Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)
Patents Act 1990 (Cth) s 105(1)
Cases cited: Commissioner of Taxation v Rio Tinto Ltd (2006) 151 FCR 341
Council of the New South Wales Bar Association v Archer (2008) 72 NSWLR 236
CSL Ltd v Novo Nordisk Pharmaceuticals Pty Ltd (2010) 87 IPR 134
DSE (Holdings) Pty Ltd v Intertan Inc (2003) 127 FCR 499
Ferella & Anor v Official Trustee in Bankruptcy (2010) 188 FCR 68
Macquarie Bank v Arup [2016] FCAFC 117
Mann v Carnell (1999) 201 CLR 1
Smith Kline & French Laboratories Ltd v Evans Medical Ltd [1989] 1 FSR 561
Telstra Corporation Ltd v BT A/asia Pty Ltd (1998) 85 FCR 152
Thomason v Campbelltown Municipal Council (1939) 39 SR (NSW) 347
United States Surgical Corp v Hospital Products International Pty Ltd (unreported, Supreme Court, NSW, McLelland J, 13 October 1981)
Date of hearing: 17 May 2018 Registry: New South Wales Division: General Division National Practice Area: Intellectual Property Sub-area: Patents and associated Statutes Category: Catchwords Number of paragraphs: 57 Counsel for the Applicant: Mr D Shavin QC with Ms L Thomas Solicitor for the Applicant: DLA Piper Australia Solicitor for the First Respondent: Mr S Sloan of Dentons Counsel for the Second Respondent: Mr N Murray with Ms F St John Solicitor for the Second Respondent: Herbert Smith Freehills ORDERS
NSD 656 of 2017 BETWEEN: NEURIM PHARMACEUTICALS (1991) LTD
Applicant
AND: GENERIC PARTNERS PTY LTD (ACN 132 833 777)
First Respondent
APOTEX PTY LTD (ACN 096 916 148)
Second Respondent
JUDGE:
NICHOLAS J
DATE OF ORDER:
24 July 2018
THE COURT ORDERS THAT:
1.The interlocutory application be dismissed.
2.The respondents pay the applicant’s costs of the interlocutory application.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
REASONS FOR JUDGMENT
NICHOLAS J:
BACKGROUND
Before me is an interlocutory application brought by the second respondent (“Apotex”) which, in substance, challenges claims for legal professional privilege and patent attorney privilege made by the applicant (“Neurim”), in respect of certain documents. The first respondent (“Generic Partners”) supports Apotex’s application and adopts its submissions.
The application arises in a proceeding for infringement of Australian Patent No 2002326114 (“the…
Keep reading for free
Create a free CaseChat account to read Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2018] FCA 1082
- Decision Date
CaseChat Overview and Summary
The court found that for a waiver to occur, it must be shown that the documents in question were likely to have affected Neurim's state of mind or that of a reasonable person in Neurim's position in some relevant way. The court held that Neurim's assertion that it did not decide that it would be desirable to amend the patent until shortly before filing the application under section 105 of the Patents Act 1990 did not constitute a waiver of privilege. The court found that Neurim did not make any express or implied assertion as to the effect of the legal advice it received regarding the amendment of the patent. The court also found that there was no inconsistency in Neurim maintaining its claim for privilege in relation to the advice it received during the prosecution of the European and United States patent applications, while asserting that it did not receive any advice in relation to the amendment of the Australian patent until in or about April 2017.
The court dismissed the interlocutory application and ordered the respondents to pay the applicant's costs of the interlocutory application. The court held that the fact that the relevant communication was unlikely to have had more than a peripheral or incidental impact on Neurim's state of mind precluded a finding of waiver. The court also held that even if the communication had affected Neurim's state of mind, there was no inconsistency in Neurim putting its state of mind in issue and withholding the documents in issue in circumstances that gave rise to some unfairness to the respondents. The court found that Neurim's assertion that a reasonable person in its position would not have decided that it was necessary or desirable to amend the patent until in or about April 2017 did not constitute a waiver of privilege.
Orders
Orders of the court
1. The interlocutory application be dismissed.
2. The respondents pay the applicant’s costs of the interlocutory application.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
The fact that the relevant communication is unlikely to have had more than a peripheral or incidental impact on the party’s state of mind is likely to preclude a finding of waiver unless the party whose state of mind is in issue makes some express or implied assertion as to the content of the relevant communication. CONSIDERATION It is common ground that Neurim’s prior knowledge and understanding as to the desirability of amending the Patent is a relevant issue in the amendment application. This would be true even if Apotex had not raised the issue of delay as a ground upon which it relies in opposing the proposed amendments: see CSL Ltd v Novo Nordisk Pharmaceuticals Pty Ltd (2010) 87 IPR 134 at [20] per Jessup J citing Smith Kline & French Laboratories Ltd v Evans Medical Ltd [1989] 1 FSR 561 at 569. Neurim’s pleaded grounds in support of its amendment application allege that Neurim seeks to amend the claims to (inter alia) better align the claims with the claims of the European Patent. It also alleges that Neurim did not decide that it would be desirable to amend the Patent until about April 2017 and that a reasonable person in Neurim’s position would also have not decided that it would be desirable to amend the Patent before then. It is important to distinguish at least two possible scenarios, one in which Neurim asserted that it had received legal advice that it was neither necessary nor desirable to seek to amend the Patent, and the other, in which it asserted that it received no advice at all on the topic before March or April 2017. The present case is within the second category. Neurim is not seeking to rely on the legal advice it obtained during the prosecution of either the European Patent Application or the United States Patent Application nor is it making any express or implied assertion as to the effect of that advice. I do not see any inconsistency in Neurim maintaining its claim for privilege in relation to such advice as it did receive in the course of prosecuting those applications while bringing a case in which it asserts that it did not receive any advice in relation to the amendment of the Patent until in or about April 2017. However, as previously explained, it may be sufficient to bring about a waiver if the person claiming privilege makes assertions about his or her state of mind in circumstances where the confidential communications are likely to have affected that state of mind (Archer at [48]). The allegation that a reasonable person in Neurim’s position would not have decided that it was necessary or desirable to amend the Patent until in or about April 2017 would usually be addressed by reference to the information that was available to Neurim which may, of course, include any legal advice Neurim received relevant to that decision. But the fact that the legal advice is relevant to the decision to amend does not of itself bring about a waiver of privilege. It must first be shown that the documents in issue are likely to have affected Neurim’s state of mind, or that of a reasonable person in Neurim’s position, in some relevant way. Even then, a waiver will only arise where there is an inconsistency in Neurim putting its state of mind in issue and withholding the documents in issue in circumstances that give rise to some unfairness to the respondents.